Louis Bessette, MD, MSc

Centre de l'Ostéoporose et de Rhumatologie de Québec
Quebec, QC, Canada

Louis Bessette, MD, FRCP(C), M.Sc.
Rheumatologist, Centre Hospitalier Universitaire de Québec, Pavillon CHUL
Assistant professor at Laval University

Dr. Bessette completed his medical training in rheumatology at Laval University in 1993. From 1994 to 1996, he received a formation in clinical research at the Multipurpose Arthritis Center of the Brigham and Women’s hospital in Boston. During the same period, he completed a master degree in epidemiology at the Harvard School of Public Health.

Louis Bessette is Co-Director for Quebec City CaMos, a Canadian epidemiologic study in osteoporosis. He is also the Program Officer for the Quebec Recognizing Osteoporosis and its Consequences (ROCQ) Program. This program evaluates the diagnostic and treatment rates of osteoporosis following fragility fractures in women, aged 50 years and over. He is the past director of the rheumatology training program at Laval University.

He is the author and co-author of more than 80 scientific manuscripts and 400 abstracts. His major research interests include rheumatoid arthritis, spondyloarthritis, osteoarthritis, osteoporosis, quality of life aspect of musculoskeletal diseases and pharmacoeconomic studies.

Disclosure information not submitted.

Presentation(s):

0297: Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Saturday, November 12, 2022
1:00 PM – 3:00 PM Eastern Time
0298: Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study
Saturday, November 12, 2022
1:00 PM – 3:00 PM Eastern Time
1422: Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice
Sunday, November 13, 2022
1:00 PM – 3:00 PM Eastern Time
0297: Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Monday, November 14, 2022
1:15 PM – 1:20 PM Eastern Time
2143: Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Monday, November 14, 2022
1:00 PM – 3:00 PM Eastern Time